Cardiovascular Biomarkers

1. Front Matter

   Pages i-xvii

   PDF

2. Biomarkers of Necrosis

   1. Front Matter

      Pages 1-1

      PDF

   2. Biomarkers of Myocardial Necrosis

      • Robert H. Christenson, Hassan M. E. Azzazy

      Pages 3-25

   3. Analytical Issues for Clinical Use of Cardiac Troponin

      • Alan H. B. Wu

      Pages 27-40

   4. Defining Myocardial Infarction

      • Allan S. Jaffe, Luciano Babuin

      Pages 41-59

   5. Biomarkers in the Emergency Department

      • Jin H. Han, W. Brian Gibler

      Pages 61-77

   6. Cardiac Troponin for Risk Assessment and Management of Non-ST-Elevation Acute Coronary Syndrome

      • Bertil Lindahl

      Pages 79-92

   7. Biomarkers of Necrosis for Risk Assessment and Management of ST-Elevation Myocardial Infarction

      • Evangelos Giannitsis, Hugo A. Katus

      Pages 93-102

   8. Cardiac Troponin After Revascularization Procedures

      • Warren J. Cantor, L. Kristin Newby

      Pages 103-118

   9. Biomarkers of Necrosis in Heart Failure

      • Emil Missov, James Rider, Leslie Miller

      Pages 119-128

   10. Is There a Role for Cardiac Troponin and Other Biomarkers in Patients With Pulmonary Embolism?

       • Samuel Z. Goldhaber

       Pages 129-137

   11. Cardiac Troponin in Conditions Other Than Acute Coronary Syndromes

       • Fred S. Apple, David A. Morrow

       Pages 139-159

   12. Degradation of Cardiac Troponins

       • Allan S. Jaffe, Jennifer E. Van Eyk

       Pages 161-174

3. Biomarkers of Ischemia

   1. Front Matter

      Pages 175-175

      PDF

   2. Developing a Marker of Ischemia

      • Robert L. Jesse

      Pages 177-192

   3. Emerging Biomarkers of Myocardial Ischemia

      • Jesse E. Adams

      Pages 193-203

4. Biomarkers of Inflammation

   1. Front Matter

      Pages 205-205

      PDF

   2. Inflammation in Cardiovascular Disease

      • Peter Libby

      Pages 207-221

   3. Analytic Issues for Clinical Use of C-Reactive Protein

      • Nader Rifai

      Pages 223-235

   4. C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention

      • Shari S. Bassuk, Paul M. Ridker

      Pages 237-260

In the four pages committed to a discussion of myocardial infarction in the first edition of Harrison’s Principles of Internal Medicine, published in 1950, there was no mention of use of the laboratory for management of patients. Thirty years later, when the first edition of Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine was published, 2 out of the 1943 pages in the text contained a discussion of the laboratory examinations in acute myocardial infarction. Our knowledge base of the multitude of ways that physicians can and should use the clinical chemistry laboratory has expanded dramatically since these classic texts were published. The nomenclature has changed: terms such as “cardiac enzymes” have given way to “cardiac biomarkers. ” The number of assays has multiplied, and the operating characteristics of available assays are impr- ing at a gratifying but dizzying rate. We now use biomarkers to diagnose cardiovascular diseases and also to frame our treatment strategies. Thus, there is a clear need for a scholarly compilation of the state of the art of cardiac biomarkers. Dr. David Morrow has expertly edited an authoritative book that answers this need. The 34 chapters in Cardiovascular Biomarkers: Pathophysiology and Disease Mana- ment were written by a group of individuals who are internationally recognized thought leaders and experts in clinical and laboratory medicine.

• cardiovascular
• heart
• heart disease
• myocardial infarction
• physiology
• vascular disease

From the Foreword...

"...readers of this text will find it an invaluable resource regardless of their familiarity with the subject."

From the reviews:

"This book provides a clear presentation of the use of biomarkers in the diagnosis and treatment of cardiovascular diseases. … The author seeks to provide clinicians with an authoritative book on the current state-of-the art in cardiovascular biomarkers. … It is aimed at practicing cardiologists and does an excellent job of defining the development and use of the current set of cardiovascular biomarkers as well as providing insight into the future directions of the field." (Cooper Woods, Doody’s Review Service, March, 2008)

• Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston

  David A. Morrow

Policies and ethics